Company news

Akebia Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Akebia Announces Swissmedic Approval of Vafseo® (vadadustat)

June 19, 2023

Akebia Therapeutics Announces New Chief Financial Officer

June 12, 2023

Akebia Therapeutics to Present at Jefferies Healthcare Conference

June 1, 2023

FDA Provides Akebia Therapeutics a Path Forward for Vadadustat

May 29, 2023

Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia

May 24, 2023

Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 21, 2023

Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

May 21, 2023

Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 7, 2023

Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights

April 30, 2023

Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

April 24, 2023

Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split

April 13, 2023

Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders

April 10, 2023

Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023

April 6, 2023

Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study

April 2, 2023

Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat

March 29, 2023

Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting

March 23, 2023

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

March 8, 2023

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights

March 1, 2023

Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

February 22, 2023

Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

February 20, 2023

Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA

December 21, 2022

Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 21, 2022

Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

November 2, 2022

Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones

October 26, 2022

Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022

October 20, 2022

Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

August 31, 2022

Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

August 3, 2022

Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)

August 3, 2022

Akebia Therapeutics to Report Second Quarter Financial Results

July 25, 2022

Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka

June 29, 2022

Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update

May 8, 2022

Akebia Therapeutics to Report First Quarter Financial Results

May 1, 2022

Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022

April 5, 2022

Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients

March 29, 2022

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

February 28, 2022

Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch

February 21, 2022

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights

February 8, 2022

Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference

January 9, 2022

Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

November 23, 2021

Akebia Therapeutics to Present at Jefferies London Healthcare Conference

November 14, 2021

Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

November 3, 2021

Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

October 31, 2021

Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease

October 28, 2021

Akebia Therapeutics to Report Third Quarter 2021 Financial Results and Highlight Recent Company Milestones

October 25, 2021

Statement from Akebia Therapeutics Regarding Litigation Against Centers for Medicare & Medicaid Services and the U.S. Department of Health and Human Services

October 24, 2021

Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021

October 17, 2021

Akebia Therapeutics Announces September 2021 Investor Conference Schedule

August 31, 2021

Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones

August 4, 2021

Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights

July 25, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.